ERBB2 and breast cancer: BRCAness score showed moderate correlation with pathological complete response (pCR) rate in both TNBC and ER-positive/HER2-negative breast cancer (Fig. 6B, AUC = 0.624 and 0.714, respectively) in GSE25066 cohort, which received anthracycline and taxane neoadjuvant chemotherapy (n = 508).